Zobrazeno 1 - 10
of 104
pro vyhledávání: '"Thomas N. Hangartner"'
Autor:
Amanda E. Marker, David F. Short, Talia Eldar-Geva, Harry J. Hirsch, Varda Gross-Tsur, Maayan Tiomkin, Ari Zimran, Thomas N. Hangartner
Publikováno v:
Journal of Orthopaedic Translation, Vol 2, Iss 4, Pp 236-237 (2014)
Externí odkaz:
https://doaj.org/article/21ebe54ec0ed4d619f39a95831a85f9b
Publikováno v:
Journal of Orthopaedic Translation, Vol 2, Iss 4, Pp 205-206 (2014)
Externí odkaz:
https://doaj.org/article/7f08fbee20db446ab9bd3753f2635466
Autor:
David F. Short, Thomas N. Hangartner, Vicente Gilsanz, Heidi J. Kalkwarf, Joan M. Lappe, Sharon Oberfield, John A. Shepherd, Babette S. Zemel, Karen Winer
Publikováno v:
Journal of Orthopaedic Translation, Vol 2, Iss 4, p 205 (2014)
Externí odkaz:
https://doaj.org/article/ad9f1fe7f4054a3c881d609834639b03
Autor:
Jeffrey Teckman, Nathan P. Goodrich, Jean P. Molleston, Amanda E. Marker, Averell H. Sherker, Karen F. Murray, Ronald J. Sokol, Saul J. Karpen, Benjamin L. Shneider, Kathleen B. Schwarz, Thomas N. Hangartner, Estella M. Alonso, John C. Magee, Philip J. Rosenthal, Cathie Spino, Binita M. Kamath, James E. Heubi, Paula M. Hertel, Robert H. Squires, Yumirle P. Turmelle, Kathleen M. Loomes
Publikováno v:
Hepatology. 69:245-257
Osteopenia and bone fractures are significant causes of morbidity in children with cholestatic liver disease. Dual-energy X-ray absorptiometry (DXA) analysis was performed in children with intrahepatic cholestatic diseases who were enrolled in the Lo
Autor:
Antti Koskela, Naila Khalil, Thomas N. Hangartner, Ramzi W. Nahhas, Masato Honda, James R. Ebert, Kurunthachalam Kannan, Miryoung Lee
Publikováno v:
Environmental Research. 160:314-321
Perfluoroalkyl substances (PFASs), including perfluorooctanoic acid (PFOA), perfluorooctane sulfonic acid (PFOS), perfluorohexane sulfonic acid (PFHxS), and perfluorononanoic acid (PFNA), have been associated with adverse bone, and metabolic changes
Autor:
Maayan Tiomkin, David F. Short, Talia Eldar-Geva, Harry J. Hirsch, Ari Zimran, Thomas N. Hangartner, Varda Gross-Tsur
Publikováno v:
Osteoporosis International. 27:3457-3464
Anthropometric adjustments of bone measurements are necessary in Prader-Willi syndrome patients to correctly assess the bone status of these patients. This enables physicians to get a more accurate diagnosis of normal versus abnormal bone, allow for
Autor:
Eric Crombez, Atul Mehta, Thomas N. Hangartner, Yune Kunes, Laurie D. Smith, Ari Zimran, Nan Wang, Joel Charrow, Derralynn Hughes, Suma P. Shankar, Deborah Elstein, P Giraldo
Publikováno v:
American Journal of Hematology. 90:592-597
Gaucher disease (GD) is a lysosomal storage disorder; symptomatic patients with type 1 GD need long-term disease-specific therapy of which the standard of care has been enzyme replacement therapy (ERT). Thirty-eight of 40 patients (aged 9–71 years)
Autor:
John A. Shepherd, Heidi J. Kalkwarf, Thomas N. Hangartner, Babette S. Zemel, Karen K. Winer, Vicente Gilsanz, Patrice Watson, Sharon E. Oberfield, Joan M. Lappe
Publikováno v:
Journal of Bone and Mineral Research. 30:156-164
Childhood and adolescence are critical periods of bone mineral content (BMC) accrual that may have long-term consequences for osteoporosis in adulthood. Adequate dietary calcium intake and weight-bearing physical activity are important for maximizing
Autor:
Antonio Cabal, Sherri L. Motzel, Bernard J. Dardzinski, Le T. Duong, Parker D. Mathers, Lynn Cook, Alan T. Savitz, Diane Posavec, Swanand Sardesai, Christopher T. Winkelmann, Donald S. Williams, Thomas N. Hangartner, Eual A. Phillips, Paul J. McCracken, Richa Y. Jayakar, John Szumiloski, Boyd B. Scott, Richard Hargreaves, Jeffrey L. Evelhoch
Publikováno v:
Bone. 56:497-505
Translational evaluation of disease progression and treatment response is critical to the development of therapies for osteoporosis. In this study, longitudinal in-vivo monitoring of odanacatib (ODN) treatment efficacy was compared to alendronate (AL
Autor:
Oliver Semler, Éva Hosszú, Nick Bishop, Christine P Burren, Jordi Anton, María Loreto Reyes, Joseph M. Lane, Horacio Plotkin, Eckhard Schoenau, Thomas N. Hangartner, Outi Mäkitie, Helene Pavlov, Jean-Pierre Devogelaer, Cathleen L. Raggio, S Faisal Ahmed, David Sillence, Ana Paredes, Silvano Adami, Paul Arundel, Roman S. Lorenc, Robert D. Steiner, Craig F Munns
Publikováno v:
The Lancet. 382:1424-1432
Children with osteogenesis imperfecta are often treated with intravenous bisphosphonates. We aimed to assess the safety and efficacy of risedronate, an orally administered third-generation bisphosphonate, in children with the disease.In this multicen